BioSpace News Archive

SRK-015 is an inhibitor of the activation of myostatin, which Scholar Rock believes has the potential to be the first muscle-directed therapy to reverse or prevent muscle atrophy in SMA patients.

Biostage, Inc. announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD).

Genprex, Inc. announced the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share, before underwriting discounts.

Stellar Biotechnologies, Inc. initiated the second phase of an expansion project at the Port of Hueneme, north of Los Angeles, California.

ActoBio Therapeutics have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019.

Addition of new facilities supports strong company-wide growth initiative

Aditlys gives patients that are going through dialysis the ability to grow artificial veins using the first polymer-based vascular access solution of this kind

The Medicrea® Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered spinal device design and manufacturing with UNiD ASI™ (Adaptive Spine Intelligence) technology, announced today that the Company has signed a joint-venture agreement with Motion Medical

Tafamidis Demonstrated a Statistically Significant Reduction in the Combination of All-cause Mortality and Frequency of Cardiovascular-related Hospitalizations in Global Trial Currently, There are No Approved Pharmacological Medications Specifically Indicated for Treating Transthyretin Cardiomyopathy

Chandler Innovations Client’s New Therapy Extending Active Life of Animals